Form 4: Viemed CFO's Routine Share Vesting and Tax Settlement

Viemed Healthcare's CFO, Trae Fitzgerald, reported the scheduled vesting of restricted stock and phantom share units, alongside tax-related share dispositions.

Summary

• Trae Fitzgerald, Chief Financial Officer of Viemed Healthcare, Inc. (VMD), reported transactions on January 29, 2026, related to the vesting of equity awards.
• Fitzgerald acquired 9,794 common shares through the vesting of Restricted Stock Units (RSUs).
• Concurrently, 2,679 common shares were disposed of to satisfy tax obligations arising from the RSU vesting, based on a market closing price of $7.48 per share.
• Fitzgerald also acquired 3,265 common shares from the vesting of cash-settled Phantom Share Units (PSUs).
• These 3,265 common shares acquired from PSU vesting were simultaneously disposed of for cash settlement, also at a market closing price of $7.48 per share.
• Following these transactions, Fitzgerald's direct beneficial ownership of common shares is 105,638.
• Fitzgerald continues to beneficially own 9,794 Restricted Stock Units and 3,264 Phantom Share Units as derivative securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting routine, pre-scheduled executive compensation transactions rather than discretionary trading that would signal a change in insider sentiment or company fundamentals.

Positives

• The vesting of Restricted Stock Units and Phantom Share Units represents a scheduled component of executive compensation, aligning management's interests with shareholders.
• The transactions are routine and reflect the execution of pre-established equity incentive plans.

Negatives

• A total of 2,679 common shares were disposed of to cover tax liabilities, reducing the direct share count held by the CFO.
• An additional 3,265 common shares were disposed of for cash settlement of Phantom Share Units, further reducing direct share ownership.

Future Outlook

The Restricted Stock Units and Phantom Share Units granted on January 29, 2024, vest in three equal annual installments, indicating future vesting events on subsequent anniversaries of the grant date.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as the vesting of equity awards and subsequent tax-related share sales, are a standard component of executive compensation packages across various industries, including healthcare. These events are typically pre-scheduled and do not necessarily reflect discretionary trading decisions by the insider.

Comparison to Industry Standards

• The use of Restricted Stock Units and Phantom Share Units as part of executive compensation is a common practice among publicly traded companies, aligning with global benchmarks for incentivizing and retaining key management personnel.
• The disposition of shares to cover tax obligations upon vesting is a standard and expected procedure in equity compensation plans across comparable companies in the healthcare sector.

Stakeholder Impact

• Shareholders: The transactions are routine and part of executive compensation, with minimal direct impact on the company's overall share structure or valuation.
• Employees: Reflects standard compensation practices for senior management.

Next Steps

• Future annual installments of the Restricted Stock Units and Phantom Share Units are expected to vest on subsequent anniversaries of the January 29, 2024, grant date.

Key Dates

Recommendation

This filing details routine, pre-scheduled vesting of executive equity awards and subsequent tax-related share dispositions. These transactions do not reflect discretionary buying or selling by the CFO and therefore do not provide new fundamental information to alter an investment decision. An investor should hold their position based on existing company fundamentals and market outlook.

Keywords

Viemed Healthcare, VMD, Form 4, Insider Transaction, Restricted Stock Units, Phantom Share Units, Executive Compensation, Share Vesting, CFO